Republic of the Philippines

Cebu Normal University

Osmeña Blvd. Cebu City, 6000 Philippines

College of Nursing
Center of Excellence (COE) | Level IV Re-Accredited (AACCUP)
Telephone No.: (032) 254 4837
Email: cn@cnu.edu.ph/secretary@cnunursing.org
DRUG STUDY

Patient’s Initials: M. S. Date of Admission: April 25, 2021 Diagnosis: Osteoporosis

Age: 65 years old Height: 160 cm Weight: 50 kg Clinical Intervention: Osteoporosis Screening
Sex: Female Ward: Orthopedic Ward Bed No.: 8 Name of Physician: Dr. Alex Morales

Name of Mechanism of Nursing

Classification Indication Contraindication Side Effects
Drug Action Responsibilities
Generic Pharmacologic Fenofibric acid General Indications: Contraindicated CNS: Before:
Name: Class: primarily inhibits With dietary therapy to in: Hypersensitivity; fatigue/weakness, ● Check doctor’s order.
Fenofibrate Fibric acid triglyceride decrease LDL Hepatic impairment headache. ● Check medication,
derivatives synthesis. cholesterol, total (including primary CV: medication’s expiration
Trade Name: cholesterol, biliary cirrhosis); PULMONARY EMBOLISM, date and dosage before
Antara Therapeutic Therapeutic triglycerides, and Pre-existing arrhythmias, deep vein administering drug. 
Class: Effects: apolipoprotein B in adult gallbladder disease; thrombosis. GI: ● Obtain a diet history,
Minimum Lipid-lowering Lowering of patients with Severe renal cholelithiasis, especially with regard to
dose: agents cholesterol and hypercholesterolemia or impairment; pancreatitis. fat consumption. Every
30 mg triglycerides with mixed dyslipidemia. Concurrent use of Derm: rash, urticaria. attempt should be made
Pregnancy subsequent With dietary HMG-CoA reductase Metab: decrease HDL to obtain normal serum
Maximum Category: decreased risk of management in the inhibitors; Lactation: levels. triglyceride levels with
dose: C pancreatitis. treatment of Potential for MS: rhabdomyolysis. diet, exercise, and weight
200 mg hypertriglyceridemia tumorigenicity noted Misc: hypersensitivity loss in obese patients
Pharmacokinetic (types IV and V in animal studies; reactions. before fenofibrate therapy
Patients’ s hyperlipidemia) in discontinue breast is instituted.
Dose Absorption: patients who are at risk feeding. Use Interactions ● Assess patient for
40 mg Well absorbed for pancreatitis and do Drug-Drug: cholelithiasis. If symptoms
(60%) after oral not respond to nondrug Cautiously in: Increase anticoagulant occur, gallbladder studies
Route: administration; therapy. Concurrent warfarin effects of warfarin. HMG- are indicated. Discontinue
PO absorption increase or HMGCoA CoA reductase inhibitors therapy if gallstones are
by food. Patient’s Indication:  reductase inhibitor increase risk of found.
Frequency: To reduce patient’s total therapy. rhabdomyolysis ● Lab Test
OD Distribution: cholesterol, LDL, and OB: Embryocidal and (concurrent use should Considerations: Monitor
Unknown. Protein triglycerides. teratogenic in animal be avoided). Absorption serum lipids before
Form: Binding: 99%. studies; use only if is decrease by bile acid therapy to determine
Tablet potential benefits sequestrants(fenofibrate consistent elevations,
Metabolism and outweigh risks to the should be given 1 hr then monitor periodically
Availability: Excretion: fetus. before or 4–6 hr after). during therapy.
(generic Rapidly converted Pedi: Safety not Increase risk of
available) to fenofibric acid, established. nephrotoxicity with During:
Tablets which is the active Geri: Age-related cyclosporine. Concurrent ● Verify client’s identity.
(Tricor): 48 metabolite; decrease in renal use with colchicine may ● Inform client of the
mg, 145 mg. fenofibric acid is function may make increase risk of purpose of the drug.
Cost: Generic metabolized by the older patients more rhabdomyolysis. ● Make sure to administer
— 48 mg liver. Fenofibric susceptible to adhering to the patient’s
$171.86/90, acid and its adverse reactions. rights in medication
145 mg metabolites are administration such as
$515.58/90. primarily excreted right drug, dosage,
Tablets in urine (60%). patient, route, and time.
(Fenoglide): ● Monitor serum AST and
40 mg, 120 Half-life: ALT periodically during
mg. Cost: 40 20 hr. therapy. May cause
mg $289.44/ increase levels. Therapy
90, 120 mg should be discontinued if
$869.40/90. levels rise more than 3
Tablets times the normal limit.
(Triglide): 50 ● If patient develops
mg, 160 mg. muscle tenderness during
Cost: Generic therapy, monitor CPK
—160 mg levels. If CPK levels are
$176.40/100. markedly increase or
Micronized myopathy occurs,
tablets discontinue therapy.
(Lofibra): 54 ● May cause mild to
mg, 100 mg, moderate increase in
160 mg. Cost: hemoglobin, hematocrit,
Generic—54 and WBCs. Monitor
mg periodically during first 12
$71.29/90, months of therapy. Levels
160 mg usually stabilize during
$213.88/90. long-term therapy.
Micronized ● Monitor prothrombin
capsules levels frequently until
(Antara): 30 levels stabilize in patients
mg, 90 mg. taking anticoagulants
Capsules concurrently.
(Lipofen): 50 ● Instruct patient to take
mg, 150 mg. medication as directed,
Cost: 50 mg not to skip doses or
$213.58/90, double up on missed
150 mg doses. Medication helps
$468.24/90. control but does not cure
Micronized elevated serum
capsules triglyceride levels.
(Lofibra): 67
mg, 134 mg, After:
200 mg. Cost: ● Instruct patient to take
Generic—67 medication as directed.
mg ● Advise patient that this
$74.95/100, medication should be
134 mg used in conjunction with
$199.62/100, diet restrictions (fat,
200 mg cholesterol,
$266.45/100. carbohydrates, alcohol),
exercise, and cessation of
smoking.
● Instruct patient to
notify health care
professional if
unexplained muscle pain,
tenderness, or weakness
occurs, especially if
accompanied by fever or
malaise.
● Advise patient to notify
health care professional of
medication regimen
before treatment or
surgery.
● Instruct female patients
to notify health care
professional promptly if
pregnancy is planned or
 suspected.
● Emphasize the
importance of follow-up
exams to determine
effectiveness and to
monitor for side effects.
• Document the medicine
administered.  
References: References: References: References: References: References: References:

Vallerand, Vallerand, A.H., Vallerand, A.H., Vallerand, A.H., Sanoski, Vallerand, A.H., Vallerand, A.H., Sanoski, Vallerand, A.H., Sanoski,
A.H., Sanoski, Sanoski, C.A., & Sanoski, C.A., & C.A., & Deglin, J.H. Sanoski, C.A., & C.A., & Deglin, J.H. C.A., & Deglin, J.H.
C.A., & Deglin, J.H. Deglin, J.H. (2017). (2017). Davis’s Drug Deglin, J.H. (2017). (2017). Davis’s Drug (2017). Davis’s Drug
Deglin, J.H. (2017). Davis’s Davis’s Drug Guide Guide for Nurses, 15th Davis’s Drug Guide Guide for Nurses, 15th Guide for Nurses, 15th ed.
(2017). Drug Guide for for Nurses, 15th ed. Philadelphia: F.A. for Nurses, 15th ed. ed. Philadelphia: F.A. Philadelphia: F.A. Davis
Davis’s Drug Nurses, 15th ed. ed. Philadelphia: Davis Company. Philadelphia: F.A. Davis Company. Company.
Guide for Philadelphia: F.A. Davis Davis Company.
Nurses, 15th F.A. Davis Company. MIMS. (n. d.). MIMS. (n. d.). MIMS. (n. d.).
ed. Company. Fenofibrate. Retrieved MIMS. (n. d.). Fenofibrate. Retrieved Fenofibrate. Retrieved
Philadelphia: MIMS. (n. d.). from Fenofibrate. from from
F.A. Davis MIMS. (n. d.). Fenofibrate. https://www.mims.com/ Retrieved from https://www.mims.com/p https://www.mims.com/p
Company. Fenofibrate. Retrieved from philippines/drug/info/fen https://www.mims.c hilippines/drug/info/fenof hilippines/drug/info/fenofi
Retrieved from https://www.mims. ofibrate?mtype=generic. om/philippines/drug/ ibrate?mtype=generic. brate?mtype=generic.
MIMS. (n. d.). https://www.mi com/philippines/dr info/fenofibrate?
Fenofibrate. ms.com/philippin ug/info/fenofibrate mtype=generic.
Retrieved es/drug/info/fen ?mtype=generic.
from ofibrate?
https://www. mtype=generic.
mims.com/phil
ippines/drug/i
nfo/fenofibrat
e?
mtype=generi
c.

PRODUCT ASSESSMENT RUBRICS FOR DRUG

STUDY
Student Name: Rose Leen T. Year/Section: BSN-3B Date: April 26, 2021 Score: /30
Rosell
Directions: Please select the appropriate rating using the following descriptions.

Elemen Very Satisf Needs Comme

t Satisfacto actory Improveme nts
ry nt
Drug ☐ Accurately presented all of the patient ☐ Accurately presented most of the ☐ Accurately presented some of the patient
Infor and drug information (name [brand & patient and drug information related to and drug information related to the case. 2
matio generic], dosage [patient’s dose; min. & the case. 1 missing information or error or more missing information or errors
n max], frequency, route, availability, noted. [2] noted. [1]
(10% contents) related to the case. [3]
)
Classifi ☐ Accurately presented the classification ☐ Accurately presented the classification ☐ Inaccurately presented the classification
catio (therapeutic and pharmacologic) related to related to the drug but with 1 irrelevant related to the drug. Classification is not
n the drug. [3] information or error noted. [2] relevant to the drug. [1]
(10
%)
☐ Accurately presented the indication/s ☐ Accurately presented the indication/s ☐ Inaccurately presented the indication/s
Indication
(general & patient- specific) related to the related to the drug but with 1 irrelevant related to the drug. Indication is not
(10%)
drug. [3] information or error noted. [2] relevant to the drug. [1]
Mechan ☐ Accurately presented the ☐ Accurately presented the mechanism ☐ Inaccurately presented the mechanism of
ism of mechanism of action of action of the drug but with 1 irrelevant action of the drug. Mechanism of action is
Action
(pharmacokinetics, pharmacodynamics) of information or error noted. [2] not relevant to the drug. [1]
(10%)
the drug. [3]
☐ Accurately presented all of the common ☐ Accurately presented most of the ☐ Accurately presented some of the
Contraind
contraindications related to the drug. [3] common contraindications related to the common contraindications related to the
icatio
drug. 1 missing information or error drug. 2 or more missing information or
n
noted. [2] errors noted. [1]
(10%
)
Side ☐ Accurately presented all of the common ☐ Accurately presented most of the ☐ Accurately presented some of the
Effe side effects related to the drug. [3] common side effects related to the drug. common side effects related to the drug. 3
cts 1-2 missing information or errors noted. or more missing information or errors
(10
%) [2] noted. [1]
Nursing ☐ Accurately presented all of the ☐ Accurately presented most of the ☐ Accurately presented some of the
Respons common nursing responsibilities (before, common nursing common nursing
ibilities during, and after) related to the drug. [9] responsibilities related to the drug. 1-2 responsibilities related to the drug. 3 or
(30%)
missing information or errors noted. [7] more missing information or errors noted.
 [3]
Refer ☐ Presented at least 2 sources that are ☐ Presented only one source that is ☐ No source was presented. Sources are not

enc updated (within 5 years), relevant, and updated (within 5 years), relevant, and updated (more than 5 years), relevant, and
es credible. [3] credible. Other sources are not updated, credible. [1]
(10 credible or relevant. [2]
%)
Sub-score = = =

Evaluated by:

Signature over Printed Name of Clinical Instructor